JPWO2020064004A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020064004A5
JPWO2020064004A5 JP2021517766A JP2021517766A JPWO2020064004A5 JP WO2020064004 A5 JPWO2020064004 A5 JP WO2020064004A5 JP 2021517766 A JP2021517766 A JP 2021517766A JP 2021517766 A JP2021517766 A JP 2021517766A JP WO2020064004 A5 JPWO2020064004 A5 JP WO2020064004A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
sodium
pharmaceutical composition
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021517766A
Other languages
English (en)
Japanese (ja)
Other versions
JP7338896B2 (ja
JP2022502448A (ja
Publication date
Priority claimed from CN201811160163.0A external-priority patent/CN110963958A/zh
Application filed filed Critical
Publication of JP2022502448A publication Critical patent/JP2022502448A/ja
Publication of JPWO2020064004A5 publication Critical patent/JPWO2020064004A5/ja
Application granted granted Critical
Publication of JP7338896B2 publication Critical patent/JP7338896B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021517766A 2018-09-30 2019-09-30 Mdm2阻害剤、その調製方法、医薬組成物および応用 Active JP7338896B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811160163.0A CN110963958A (zh) 2018-09-30 2018-09-30 一种mdm2抑制剂,及其制备方法、药物组合物和应用
CN201811160163.0 2018-09-30
PCT/CN2019/109428 WO2020064004A1 (fr) 2018-09-30 2019-09-30 Inhibiteur de mdm2, son procédé de préparation, composition pharmaceutique associée et utilisation correspondante

Publications (3)

Publication Number Publication Date
JP2022502448A JP2022502448A (ja) 2022-01-11
JPWO2020064004A5 true JPWO2020064004A5 (fr) 2022-12-06
JP7338896B2 JP7338896B2 (ja) 2023-09-05

Family

ID=69949744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517766A Active JP7338896B2 (ja) 2018-09-30 2019-09-30 Mdm2阻害剤、その調製方法、医薬組成物および応用

Country Status (7)

Country Link
US (1) US11299460B2 (fr)
EP (1) EP3858812A4 (fr)
JP (1) JP7338896B2 (fr)
KR (1) KR102610545B1 (fr)
CN (2) CN110963958A (fr)
AU (1) AU2019351530B2 (fr)
WO (1) WO2020064004A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114853731A (zh) * 2021-02-04 2022-08-05 上海长森药业有限公司 一种双功能mdm2蛋白降解剂,及其制备方法、药物组合物和应用
WO2023089375A1 (fr) * 2021-11-22 2023-05-25 Ligature Therapeutics Pte, Ltd. Composés thérapeutiques et leurs procédés d'utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9376425B2 (en) * 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
JP6266659B2 (ja) * 2013-02-28 2018-01-24 アムジエン・インコーポレーテツド 癌の治療のための安息香酸誘導体mdm2阻害剤
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
WO2015070224A2 (fr) * 2013-11-11 2015-05-14 Amgen Inc. Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
BR112018070549A2 (pt) * 2016-04-06 2019-02-12 The Regents Of The University Of Michigan degradantes de proteína mdm2
WO2017176958A1 (fr) * 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Intermédiaires monofonctionnels pour la dégradation d'une protéine cible dépendante du ligand
ES2880149T3 (es) * 2016-11-15 2021-11-23 Novartis Ag Dosis y régimen para inhibidores de la interacción HDM2-p53

Similar Documents

Publication Publication Date Title
JP2007509055A (ja) [2−(8,9−ジオキソ−2,6−ジアザビシクロ[5.2.0]ノナ−1(7)−エン−2−イル)アルキル]ホスホン酸および誘導体の経口投与
HU197840B (en) Process for producing synergic pharmaceutical compositions comprising amantadin and selegilin
AU2018420535B2 (en) Edaravone pharmaceutical composition
CA2603783C (fr) Compositions pharmaceutiques presentant des profils de dissolution ameliores pour des medicaments peu solubles
JP2017200931A (ja) スルフォラファンの単離及び精製
JPWO2009099132A1 (ja) グルタチオンの保存安定性向上方法
RU2268727C2 (ru) Лекарственное средство, обладающее защитным действием в отношении окислительно-токсических и прежде всего кардиотоксических соединений
RU2003100507A (ru) Фармацевтические композиции
JPWO2020064004A5 (fr)
CN1263467A (zh) 用噻唑烷二酮、促胰岛素分泌剂和α一葡糖苷酶抑制剂治疗糖尿病
CN1274282A (zh) 用噻唑烷二酮和α-葡糖苷酶抑制剂治疗糖尿病
ES2249616T3 (es) Citidina-fosfocolina para el tratamiento de la neuropatia diabetica.
KR20210141203A (ko) 에르도스테인 유도체 및 이를 함유하는 약학 조성물
JP2023501968A (ja) d-アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP2629844B2 (ja) 抗寄生虫剤
US20060094685A1 (en) Medicinal composition for drug-induced neuropathy
CN103735551B (zh) 心脑血管的药物组合物及其制备方法和应用
EP0474438A1 (fr) Méthode pour la prévention et le traitement de maladies cérébrovasculaires en utilisant l'inhibiteur de l'enzyme de conversion de l'angiotensine céranapril
AT392906B (de) Pharmazeutische praeparate zur oralen verabreichung
DE69919995T2 (de) Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsis
JPS6140205B2 (fr)
JPH02262519A (ja) 糖尿病性神経障害治療剤
EP0488041A2 (fr) Une composition pharmaceutique contre l'infection de cytomégalovirus
EP4045056A1 (fr) Préparations combinées de dérivés d'acide 3-n-formylhydroxylaminopropyl phosphonique ou de dérivés d'acide 3-n-acétylhydroxylaminopropyl phosphonique avec de la clindamycine et l'artésunate
JPH01165522A (ja) 鼻及びのどの疾患の治療剤